SYTL5

Across TCGA pan-cancer cohorts, SYTL5 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of SYTL5’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SYTL5 RNA is repressed in tumor relative to normal tissue. In most cancer types SYTL5 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, THCA, and BLCA are the cancer types where SYTL5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SYTL5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−1.486	<.001	12	view →
THCA	Male	III,IV	+4.001	<.001	11	view →
BLCA	All	III,IV	+1.842	.001	8	view →
KIRP	Male	II,III,IV	−1.039	<.001	8	view →
BRCA	All	II,III,IV	+0.829	<.001	8	view →
LIHC	Male	All	−0.727	<.001	8	view →
LUSC	All	All	+0.714	.002	5	view →
PAAD	All	All	+2.780	.007	4	view →
COAD	Female	All	−0.979	.003	3	view →
HNSC	All	All	−0.628	.035	3	view →
STAD	Male	IV	−2.050	.016	2	view →
PRAD	All	All	−0.375	.014	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

SYTL5–KIRC

Open the KIRC breakdown →